Overview

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Forest Laboratories
Collaborator:
Cypress Bioscience, Inc.
Treatments:
Levomilnacipran
Milnacipran